An investor in NYSE:PBYI shares filed a lawsuit over alleged violations of Federal Securities Laws by Puma Biotechnology Inc.
Investors who purchased shares of Puma Biotechnology Inc (NYSE:PBYI) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The plaintiff claims that between February 29, 2016 and May 4, 2017, the Defendants made false and/or misleading statements and/or failed to disclose that the Company did not anticipate that the U.S. Food and Drug Administration’s (“FDA”) would ultimately approve neratinib for the treatment of breast cancer, that as such, Puma had overstated the drug’s approval prospects and/or commercial viability, and that as a result, Puma’s public statements were materially false and misleading at all relevant times.
Those who purchased NYSE:PBYI shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego